Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Learn more about Tempus Next. Chris Scotto DiVetta, SVP of Applications at Tempus AI introduces Tempus Next, an AI enabled care pathway platform that helps providers accelerate the adoption of evidence based care. Watch replay

Feb 1, 2023 · We’ve built a variety of these AI-driven algorithms at Tempus. Our Tempus|TO (or tumor origin) test uses RNA expression results from tumor metastases to predict the patient’s most likely cancer type from 68 possible diagnoses.

With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care.

Sep 12, 2024 · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx.

Nov 4, 2024 · Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with severe aortic stenosis (sAS) and severe mitral regurgitation (sMR) by identifying patients who may have been previously overlooked.

Jan 13, 2025 · CHICAGO--(BUSINESS WIRE)--Jan. 13, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

Sep 4, 2024 · BioNTech will work collaboratively with Tempus to leverage Tempus’ real-world multimodal database to generate novel insights into the biological mechanisms supporting the discovery of new therapies and aiming to enhance the development of BioNTech’s clinical oncology pipeline.

Jul 16, 2024 · Tempus’ AI-enabled platform generates the type of rich multimodal data required to develop a novel class of predictive algorithms that can be introduced in the clinic to support personalized patient treatment selection.